A Pilot Study of FFP104 in Subjects With Crohn's Disease

Summary

This study will be conducted to evaluate the safety, tolerability and efficacy of intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with moderate to severely active Crohn's Disease

Timeline

Start

2016-01

Primary completion

2017-08

Completion

2017-12

Drugs

Indications